Certara, Inc. (NASDAQ:CERT) Receives $15.67 Average Price Target from Brokerages

Shares of Certara, Inc. (NASDAQ:CERT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $15.67.

CERT has been the subject of a number of recent research reports. William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Stephens reissued an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. KeyCorp boosted their target price on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Finally, Barclays raised Certara from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th.

Certara Stock Up 2.2%

Certara stock traded up $0.26 during mid-day trading on Tuesday, reaching $11.88. The stock had a trading volume of 1,523,738 shares, compared to its average volume of 1,312,291. Certara has a one year low of $8.64 and a one year high of $17.76. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -59.40, a PEG ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a 50-day moving average price of $11.72 and a two-hundred day moving average price of $11.74.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. On average, analysts expect that Certara will post 0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

Hedge funds have recently modified their holdings of the business. Blue Trust Inc. grew its position in Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Certara by 3.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock valued at $253,000 after purchasing an additional 823 shares during the last quarter. Private Advisor Group LLC grew its holdings in Certara by 4.0% in the 1st quarter. Private Advisor Group LLC now owns 24,517 shares of the company's stock worth $243,000 after acquiring an additional 949 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares during the period. Finally, Invesco Ltd. lifted its position in Certara by 0.3% during the 1st quarter. Invesco Ltd. now owns 394,037 shares of the company's stock valued at $3,901,000 after acquiring an additional 1,285 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.